Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 17/20 | 0.53 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.49 |
| ▸ | OXTR | P30559 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5674386 | 0.96 | AVPR1B (0.57) | AVPR1BAVPR1AOXTRKDM4EALDH1A1 | |
| SCHEMBL1465496 | 0.93 | AVPR1B (0.60) | AVPR1BAVPR1AOXTRKDM4EALDH1A1 | |
| SCHEMBL1464935 | 0.90 | AVPR1B (0.54) | AVPR1BAVPR1AOXTRKDM4EALDH1A1 | |
| SCHEMBL5675737 | 0.88 | AVPR1B (0.58) | AVPR1BAVPR1AOXTRAVPR2 | |
| SCHEMBL5677614 | 0.86 | AVPR1B (0.53) | AVPR1BAVPR1AOXTRKDM4EALDH1A1 | |
| SCHEMBL5675846 | 0.85 | AVPR1B (0.63) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL5674035 | 0.82 | AVPR1B (0.62) | AVPR1BAVPR1AOXTR | |
| SCHEMBL1464575 | 0.82 | AVPR1B (0.55) | AVPR1BAVPR1AOXTRAVPR2GPR65 | |
| SCHEMBL74522 | 0.82 | AVPR1B (0.63) | AVPR1BKDM4EALDH1A1L3MBTL1LMNA | |
| SCHEMBL5675666 | 0.81 | AVPR1B (0.54) | AVPR1BAVPR1AOXTRKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119086-B2 | Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2006-10-10 | — | — | US | disclosed |
| US-20040180878-A1 | Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180878-A1 | Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use | AVPR2, AVPR1A, AVPR1B | AVPR1B 3/4885AVPR1A 2/4885OXTR 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.